MoneyWorks4Me

Check Before You Invest : Q-Line Biotech Ltd

BSE: 0 NSE: QLINE ISIN: INE1G2W01011
  |   Sector:  Healthcare   |   Industry:  Medical Equipment/Supplies/Accessories

Snapshot

Q.1 Which industry/sub-sector does Q-Line Biotech Ltd belong to?
Q-Line Biotech Ltd belongs to the Healthcare sector, operating specifically within the Medical Equipment/Supplies/Accessories segment.
Q.2 Is Q-Line Biotech Ltd a good quality company?
Q-Line Biotech Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q.3 Is Q-Line Biotech Ltd undervalued or overvalued?
Q-Line Biotech Ltd appears Overvalued, as its key valuation ratios are higher than their past averages.

Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more.

Valuation Ratios Current 3-year
Historic Median
Price to Earnings 28.17 -
Price to Book 6.2 -
Price to Sales 4.59 -
EV to EBITDA 16.56 -
Q.4 Is Q-Line Biotech Ltd a good buy now?
Q-Line Biotech Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Performance Analysis

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

A: What are the trends in revenue and profit margins?

Q.1 Revenue growth of Q-Line Biotech Ltd?
Q-Line Biotech Ltd revenue growth is 9.1% for FY-2026, which is below its 3-year CAGR of 23.2%, indicating slower growth.

Q.2 Gross Profit margin of Q-Line Biotech Ltd?
Q-Line Biotech Ltd Gross profit margin which is the profit after deduction of direct costs, is 23.3% for FY-2026, which is above its 3-year median of 18.8%, indicating increasing margins.

Q.3 Operating Profit Margin of Q-Line Biotech Ltd?
Q-Line Biotech Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 30.83% for FY-2026, which is above its 3-year median of 20.21% indicating increasing margins.

Q.4 Net Profit Margin of Q-Line Biotech Ltd?
Q-Line Biotech Ltd Net Profit Margin is 16.31% for FY-2026, is above its 3-year median of 10.63%, indicating increasing margins.
Current Level 3-year
Historic Median
Gross Profit Margin (%) 23.3 18.8
Operating Profit Margin (%) 30.83 20.21
Net Profit Margin (%) 16.31 10.63

B: Does the business utilize capital efficiently?

Q.5 Return on Asset of Q-Line Biotech Ltd?
Q-Line Biotech Ltd Return on Asset is 11.01%, which is above its 3-year historical median of 7.34%, indicating improved asset utilization efficiency.

Q.6 Return on capital employed (ROCE) of Q-Line Biotech Ltd?
Q-Line Biotech Ltd Return on capital employed is 22.23% for FY-2026, which is above its 3-year historical median of 16.17%. The current ROCE is above its estimated weighted average cost of capital (WACC) of 14%, indicating value creation.

Q.7 Return on Equity (ROE) of Q-Line Biotech Ltd?
Q-Line Biotech Ltd Return on equity is 25.55% for FY-2026, which is above its 3-year historical median of 14.97%, indicating the business is making better use of its shareholders capital.

Q.8 Cash conversion cycle of Q-Line Biotech Ltd?
Q-Line Biotech Ltd Cash conversion cycle is 111 days, above its 3-year historical median of 83 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level 3-year
Historic Median
Asset Turnover (x) 0.71 0.71
ROE (%) 25.55 14.97
ROCE (%) 22.23 16.17
Cash Conversion Cycle 111 days 83 days

C: How much debt does the business have and is it at a sustainable level?

Q.9 Debt to Equity ratio of Q-Line Biotech Ltd?
Q-Line Biotech Ltd Debt-to-Equity ratio is 0.92, which is above the industry average of 0.25, indicating higher debt levels in the industry.

Q.10 Debt to cash flow from operations of Q-Line Biotech Ltd?
Q-Line Biotech Ltd Debt to cash flow from operations is 13.77, which is at a unhealthy level.

Ownership & governance

D: Promoter shareholding and pledge status of Q-Line Biotech Ltd?

Q.1 Promoter shareholding and pledge status of Q-Line Biotech Ltd?
Promoters hold 67.51% of the Q-Line Biotech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

E: How does Q-Line Biotech Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Q-Line Biotech Ltd vs industry peers?
Q-Line Biotech Ltd revenue CAGR is 23.20%, compared to the industry median CAGR of 0.00%, indicating faster growth and gaining its market share.
Profit Metrics
Current Level 3-year
Industry Median
Revenue Growth (%) 9.1 0
Gross Profit Growth (%) 42.4 23.7
Operating Profit Growth (%) 58.1 18.5
Net Profit Growth (%) 250 26
Operating Efficiency
Current Level 3-year
Industry Median
Asset Turnover (x) 0.71 0.88
ROE (%) 25.55 17.27
ROCE (%) 22.23 19.94
Cash Conversion Cycle (days) 110.64 93

Valuation & price assessment

Q.1 Stock return of Q-Line Biotech Ltd over the last decade?
Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.
9Y 5Y 3Y 1Y
Share Price
CAGR
- - - -
Q.2 Valuation ratios of Q-Line Biotech Ltd vs historical?
The current P/E ratio of 28.17 is higher than its historical median of , indicating that the stock is trading above its historical average valuation.
Q.3 How do the current valuation ratios compare with 3-year historical median and industry numbers?
Valuation Ratios Current 3-year
Historic Median
3-year
Industry Median
Price to Earnings 28.17 - 32.21
Price to Book 6.2 - 4.76
Price to Sales 4.59 - 3.65
EV to EBITDA 16.56 - 19.54

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: